555 related articles for article (PubMed ID: 35361691)
21. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects.
Wheeler SE; Shurin GV; Yost M; Anderson A; Pinto L; Wells A; Shurin MR
Microbiol Spectr; 2021 Sep; 9(1):e0034121. PubMed ID: 34346750
[TBL] [Abstract][Full Text] [Related]
22. Humoral and cellular immune response and the safety of third SARS-CoV-2 mRNA vaccine with longer interval after the second vaccination in kidney transplant recipients.
Takai S; Nishida H; Ito H; Fukuhara H; Nawano T; Narisawa T; Kanno H; Yagi M; Yamagishi A; Sakurai T; Naito S; Kato T; Morikane K; Tsuchiya N
Front Immunol; 2022; 13():1050211. PubMed ID: 36532067
[TBL] [Abstract][Full Text] [Related]
23. Systemic and T cell-associated responses to SARS-CoV-2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS-CoV-2.
Woelfel S; Dütschler J; König M; Graf N; Oikonomou V; Krieger C; Truniger S; Franke A; Eckhold A; Forsch K; Wyss J; Krupka N; Albrich W; Frei N; Geissler N; Schaub P; ; Friedrich M; Misselwitz B; Korte W; Bürgi JJ; Brand S
Aliment Pharmacol Ther; 2023 Jan; 57(1):103-116. PubMed ID: 36307899
[TBL] [Abstract][Full Text] [Related]
24. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
25. Cellular and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients: An observational cohort study.
Yang LM; Costales C; Ramanathan M; Bulterys PL; Murugesan K; Schroers-Martin J; Alizadeh AA; Boyd SD; Brown JM; Nadeau KC; Nadimpalli SS; Wang AX; Busque S; Pinsky BA; Banaei N
J Clin Virol; 2022 Aug; 153():105217. PubMed ID: 35714462
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Humoral and Cellular Responses in SARS-CoV-2 mRNA Vaccinated Immunocompromised Patients.
Oyaert M; De Scheerder MA; Van Herrewege S; Laureys G; Van Assche S; Cambron M; Naesens L; Hoste L; Claes K; Haerynck F; Kerre T; Van Laecke S; Van Biesen W; Jacques P; Verhasselt B; Padalko E
Front Immunol; 2022; 13():858399. PubMed ID: 35401575
[TBL] [Abstract][Full Text] [Related]
27. Immune Responses after a Third Dose of mRNA Vaccine Differ in Virus-Naive versus SARS-CoV-2- Recovered Dialysis Patients.
Attias P; Azzaoui I; El Karoui K; de La Selle A; Sokal A; Chappert P; Grimbert P; Fernandez I; Bouvier M; Samson C; Dahmane D; Rieu P; Nizard P; Fourati S; Sakhi H; Mahévas M;
Clin J Am Soc Nephrol; 2022 Jul; 17(7):1008-1016. PubMed ID: 35764393
[TBL] [Abstract][Full Text] [Related]
28. Broad humoral and cellular immunity elicited by one-dose mRNA vaccination 18 months after SARS-CoV-2 infection.
Kang CK; Shin HM; Choe PG; Park J; Hong J; Seo JS; Lee YH; Chang E; Kim NJ; Kim M; Kim YW; Kim HR; Lee CH; Seo JY; Park WB; Oh MD
BMC Med; 2022 May; 20(1):181. PubMed ID: 35508998
[TBL] [Abstract][Full Text] [Related]
29. Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients.
Bajwa HM; Novak F; Nilsson AC; Nielsen C; Holm DK; Østergaard K; Witt AH; Byg KE; Johansen IS; Mittl K; Rowles W; Zamvil SS; Bove R; Sabatino JJ; Sejbaek T
Mult Scler Relat Disord; 2022 Apr; 60():103729. PubMed ID: 35334278
[TBL] [Abstract][Full Text] [Related]
30. Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant Recipients.
Harberts A; Schaub GM; Ruether DF; Duengelhoef PM; Brehm TT; Karsten H; Fathi A; Jahnke-Triankowski J; Fischer L; Addo MM; Haag F; Luetgehetmann M; Lohse AW; Schulze Zur Wiesch J; Sterneck M
Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2558-2566.e5. PubMed ID: 35850415
[TBL] [Abstract][Full Text] [Related]
31. Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis.
Novak F; Nilsson AC; Nielsen C; Holm DK; Østergaard K; Bystrup A; Byg KE; Johansen IS; Mittl K; Rowles W; Mcpolin K; Spencer C; Sagan S; Gerungan C; Wilson MR; Zamvil SS; Bove R; Sabatino JJ; Sejbaek T
Mult Scler Relat Disord; 2021 Nov; 56():103251. PubMed ID: 34571415
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of COVID-19 mRNA vaccination in patients with autoimmune disorders: humoral and cellular immune response.
Filippini F; Giacomelli M; Bazzani C; Fredi M; Semeraro P; Tomasi C; Franceschini F; Caruso A; Cavazzana I; Giagulli C
BMC Med; 2023 Jun; 21(1):210. PubMed ID: 37316832
[TBL] [Abstract][Full Text] [Related]
33. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study.
Jyssum I; Kared H; Tran TT; Tveter AT; Provan SA; Sexton J; Jørgensen KK; Jahnsen J; Kro GB; Warren DJ; Vaage EB; Kvien TK; Nissen-Meyer LH; Anderson AM; Grødeland G; Haavardsholm EA; Vaage JT; Mjaaland S; Syversen SW; Lund-Johansen F; Munthe LA; Goll GL
Lancet Rheumatol; 2022 Mar; 4(3):e177-e187. PubMed ID: 34977602
[TBL] [Abstract][Full Text] [Related]
34. SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod.
Meyer-Arndt L; Braun J; Fauchere F; Vanshylla K; Loyal L; Henze L; Kruse B; Dingeldey M; Jürchott K; Mangold M; Maraj A; Braginets A; Böttcher C; Nitsche A; de la Rosa K; Ratswohl C; Sawitzki B; Holenya P; Reimer U; Sander LE; Klein F; Paul F; Bellmann-Strobl J; Thiel A; Giesecke-Thiel C
J Neurol Neurosurg Psychiatry; 2022 Sep; 93(9):960-971. PubMed ID: 35835468
[TBL] [Abstract][Full Text] [Related]
35. Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma.
Ishio T; Tsukamoto S; Yokoyama E; Izumiyama K; Saito M; Muraki H; Kobayashi M; Mori A; Morioka M; Kondo T
Ann Hematol; 2023 Jun; 102(6):1421-1431. PubMed ID: 37041299
[TBL] [Abstract][Full Text] [Related]
36. Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod.
Achiron A; Mandel M; Gurevich M; Dreyer-Alster S; Magalashvili D; Sonis P; Dolev M; Menascu S; Harari G; Flechter S; Falb R
J Neurol; 2022 May; 269(5):2286-2292. PubMed ID: 35235002
[TBL] [Abstract][Full Text] [Related]
37. Immune responses to SARS-CoV-2 mRNA vaccination in people with idiopathic CD4 lymphopenia.
Rocco JM; Boswell KL; Laidlaw E; Epling B; Anderson M; Serebryannyy L; Narpala S; O'Connell S; Kalish H; Kelly S; Porche S; Oguz C; McDermott A; Manion M; Koup RA; Lisco A; Sereti I
J Allergy Clin Immunol; 2024 Feb; 153(2):503-512. PubMed ID: 38344971
[TBL] [Abstract][Full Text] [Related]
38. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.
Holroyd KB; Healy BC; Conway S; Houtchens M; Bakshi R; Bhattacharyya S; Bose G; Galetta K; Kaplan T; Severson C; Singhal T; Stazzone L; Zurawski J; Polgar-Turcsanyi M; Saxena S; Paul A; Glanz BI; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2022 Nov; 67():104079. PubMed ID: 35952457
[TBL] [Abstract][Full Text] [Related]
39. Immune response to SARS-CoV-2 mRNA vaccination in multiple sclerosis patients after rituximab treatment interruption.
Gröning R; Dernstedt A; Ahlm C; Normark J; Sundström P; Forsell MNE
Front Immunol; 2023; 14():1219560. PubMed ID: 37575257
[TBL] [Abstract][Full Text] [Related]
40. Integration of Cellular and Humoral Immune Responses as an Immunomonitoring Tool for SARS-CoV-2 Vaccination in Healthy and Fragile Subjects.
Brisotto G; Montico M; Turetta M; Zanussi S; Cozzi MR; Vettori R; Boschian Boschin R; Vinante L; Matrone F; Revelant A; Palazzari E; Innocente R; Fanetti G; Gerratana L; Garutti M; Lisanti C; Bolzonello S; Nicoloso MS; Steffan A; Muraro E
Viruses; 2023 May; 15(6):. PubMed ID: 37376576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
